文献速递结核与非结核分枝杆菌病毒性肝炎

NAT2慢乙酰化表型是抗结核药物致肝毒性的显著危险因素:多民族巢式病例对照研究结果

NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

在米兰Luigi Sacco医院结核门诊开展多民族巢式病例对照研究,纳入102例患者,每例肝毒性患者按性别、年龄、体重指数、结核/结核感染诊断及索引日期匹配2例对照。NAT2慢乙酰化状态是药物性肝损伤的最佳独立预测因素(比值比5.97,95%置信区间1.38-25.76;P=0.02)。结论认为NAT2基因型指导给药可能有助于优化抗结核治疗并防止治疗失败。

要点

  • NAT2慢乙酰化状态是抗结核药物致肝毒性的最佳独立预测因素(比值比5.97,95%置信区间1.38-25.76;P=0.02)。
  • 研究在米兰Luigi Sacco医院结核门诊的多民族患者中开展,共纳入102例患者。
  • 作者认为NAT2基因型指导给药可能有助于优化抗结核治疗并防止治疗失败。

核心结论

  • NAT2慢乙酰化状态是抗结核药物致肝毒性的最佳独立预测因素(比值比5.97,95%置信区间1.38-25.76;P=0.02)。
  • 作者认为NAT2基因型指导给药可能有助于优化抗结核治疗并防止治疗失败。

研究设计与样本

  • 在米兰Luigi Sacco医院结核门诊患者中开展巢式病例对照研究。
  • 研究纳入102例患者(平均年龄[标准差]45.6[15.6]岁)。
  • 每例肝毒性患者按性别、年龄、体重指数、结核/结核感染诊断及索引日期匹配2例对照。

主要发现

  • NAT2慢乙酰化状态是药物性肝损伤的最佳独立预测因素(比值比5.97,95%置信区间1.38-25.76;P=0.02)。

关键数值与推荐

  • NAT2慢乙酰化状态预测药物性肝损伤的比值比为5.97(95%置信区间1.38-25.76;P=0.02)。

临床怎么用

  • 作者认为NAT2基因型指导给药可能有助于优化抗结核药物治疗并防止治疗失败。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Under standard therapies, the incidence of drug-induced liver injury (DILI) in patients with tuberculosis ranges from 2% to 28%. Numerous studies have identified the risk factors for antituberculosis DILI; however, none have been conducted in a multiethnic real-world setting. The primary outcome of the current study was to identify the risk factors that could be used as the best predictors of DILI in a multiethnic cohort. METHODS: A nested case-control study was conducted in patients at the tuberculosis clinic of Luigi Sacco Hospital in Milan. RESULTS: The study included 102 patients (mean age [SD], 45.6 [15.6] years). For each patient with hepatotoxicity, 2 controls were matched for sex, age, body mass index, tuberculosis/tuberculosis infection diagnosis, and index date. We found that N-acetyltransferase 2 gene (NAT2) slow acetylator status was the best independent predictor of DILI (odds ratio, 5.97 [95% confidence interval, 1.38-25.76]; P = .02]. CONCLUSIONS: NAT2 genotype-guided dosing may help optimize antituberculosis drug treatment and prevent treatment failure. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov NCT06539455.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cheli S, Torre A, Schiuma M, et al. NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study. Clin Infect Dis. 2025. PMID: 39727196. doi:10.1093/cid/ciae583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。